Loading company
Just reported
From Biocryst Pharmaceuticals's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$180.3M
+13% y/y
-17% q/q
Guided
—
No guide given
Actual
$0.14
+133% y/y
-53% q/q
Guided
—
No guide given
Actual
$53.3M
+80% y/y
-46% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Biocryst Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$34.4BA
NBIXNeurocrine Biosciences, Inc.$16.9BA+
ELANElanco Animal Health Incorporated$13.4BA
KNSAKiniksa Pharmaceuticals International, plc$8.2BA+
LQDALiquidia Corporation$5.2BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now ABuilt from Biocryst Pharmaceuticals, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Company outlook: revenue of $625M to $645M for Fiscal year 2026 — down 27.4% on a year earlier ($874.8M)
Grade B
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Biocryst Pharmaceuticals, Inc.’s grade history. The other 39 go back to November 2016.
